Clinical trial · Observational
The Registry of Genetic Expression of Taiwan Urologic Cancer
National Health Research Institutes,Taiwan
NCT05725304CI-TRIAL-00090038active not recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This project is a nationwide precision medicine program for urothelial carcinoma and renal cell carcinoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Urologic Cancer | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (2)
- label
- kidney cancer
- description
- RCC arms: Retrospective studies for ccRCC (N=100) and nccRCC (N=100). The studies aim to obtain clinical information to correlate with genetic characterization of RCCs of all types.
- label
- urothelial cancer
- description
- UC arm: This is a prospective study for UC originated from the translational epithelium in the urinary tract (N=300). The study aims to obtain cancer tissues that originated from bladder (N=100), ureter (N=100), and renal pelvis (N=100).
Primary outcomes (1)
- measure
- Development of an integrated database of genetic background
- timeFrame
- From date of registration to 30 Sep 2029
- description
- Development of an integrated database of genetic background from populations, underlying status, clinical information, and therapeutic outcomes in carcinogen-related advanced urologic tumors.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Ages 20 and above. (Age \>= 18 years old from January 1, 2023). 2. Pathological reports showed renal cell carinoma or urothelial carcinoma. 3. muscle-invasive bladder cancer or positive of N/M grade, UTUC of T2 at least or positive of N/M grade, or stage III/IV RCC 4. Willingness to provide the residual biopsy/operative tumor samples for study. 5. Life expectancy more than 3 months. 6. Patients fully understand the protocol with the willingness to have regular follow-up. Exclusion Criteria: 1. Inability to cooperate by providing a complete medical history. 2. Ineligible tumor tissue samples for next-generation sequencing of genetic testing. 3. Undesirable compliance. 4. Having a known additional malignancy that is progressing or has required active treatment within the past 3 years. Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g., cervical carcinoma in situ) that have undergone potentially curative therapy are not excluded.
References
Publications (0)
Data not yet available
No reference posted for this study.